×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANIP – ani pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANIP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
07:48 am
anip
ANI Pharmaceuticals (ANIP) was upgraded by Zacks Research from "hold" to "strong-buy".
Low
Report
ANI Pharmaceuticals (ANIP) was upgraded by Zacks Research from "hold" to "strong-buy".
4/13
04:16 pm
anip
1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down [Yahoo! Finance]
Low
Report
1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down [Yahoo! Finance]
4/13
06:50 am
anip
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
Low
Report
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
4/8
06:50 am
anip
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
Low
Report
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
4/7
06:50 am
anip
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
Medium
Report
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
4/3
10:42 pm
anip
ANI Pharmaceuticals: Worthy Of A Position [Seeking Alpha]
Medium
Report
ANI Pharmaceuticals: Worthy Of A Position [Seeking Alpha]
3/31
08:23 pm
anip
ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease [Yahoo! Finance]
Low
Report
ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/27/2026
06:50 am
ANIP
ani pharmaceuticals, inc.
BEAT
Report
-11.0%
ani pharmaceuticals, inc.
11/7/2025
06:50 am
ANIP
ani pharmaceuticals, inc.
BEAT
Report
-1.7%
ani pharmaceuticals, inc.
5/9/2025
06:50 am
ANIP
ani pharmaceuticals, inc.
BEAT
Report
-10.5%
ani pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/13
04:40 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: Apr 13 Filed by: Cook Meredith
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: Apr 13 Filed by: Cook Meredith
4/9
04:15 pm
anip
Form ARS ANI PHARMACEUTICALS INC For: Dec 31
Low
Report
Form ARS ANI PHARMACEUTICALS INC For: Dec 31
4/9
04:13 pm
anip
Form DEFA14A ANI PHARMACEUTICALS INC
Low
Report
Form DEFA14A ANI PHARMACEUTICALS INC
4/9
04:12 pm
anip
Form DEF 14A ANI PHARMACEUTICALS INC For: Dec 31
Low
Report
Form DEF 14A ANI PHARMACEUTICALS INC For: Dec 31
4/7
04:21 pm
anip
Form 8-K ANI PHARMACEUTICALS INC For: Apr 01
Low
Report
Form 8-K ANI PHARMACEUTICALS INC For: Apr 01
3/26
03:46 pm
anip
Form SCHEDULE 13G/A ANI PHARMACEUTICALS INC Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A ANI PHARMACEUTICALS INC Filed by: VANGUARD GROUP INC
3/13
05:29 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: Mar 11 Filed by: Rowland Thomas Andrew
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: Mar 11 Filed by: Rowland Thomas Andrew
3/13
05:29 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: Mar 13 Filed by: Cook Meredith
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: Mar 13 Filed by: Cook Meredith
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL
18.7%
6/18 ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc. 10.0%
4/8 Form 4 ANI PHARMACEUTICALS INC For: Apr 06 Filed by: Schrepfer Robert W 8.0%
4/13 ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL 6.1%
9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.6%
9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. 4.1%
1/9 ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd. 3.5%
6/28 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
5/9 Q1/2019 3/31/2019 EPS 1.300 ZacksConsensus 1.030 ActVsEst 0.270 - Beat 3.1%
10/22 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.0%
6/18 ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc. 10.0%
4/8 Form 4 ANI PHARMACEUTICALS INC For: Apr 06 Filed by: Schrepfer Robert W 8.0%
4/13 ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL 6.1%
9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.6%
9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. 4.1%
1/9 ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd. 3.5%
6/28 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
5/9 Q1/2019 3/31/2019 EPS 1.300 ZacksConsensus 1.030 ActVsEst 0.270 - Beat 3.1%
10/22 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.0%
TOP News Decliners
11/6
Q3/2019 9/30/2019 EPS 1.230 ZacksConsensus 1.320 ActVsEst (0.090) - Miss
-23.7%
2/27 Q4/2019 12/31/2019 EPS 1.080 ZacksConsensus 1.020 ActVsEst 0.060 - Beat -18.7%
8/7 Q2/2019 6/30/2019 EPS 1.440 ZacksConsensus 1.180 ActVsEst 0.260 - Beat -15.1%
4/14 ANI Announces Upcoming Departure of CEO -9.0%
3/2 ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules -7.8%
3/4 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
3/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.4%
3/31 Form 4 ANI PHARMACEUTICALS INC For: Mar 28 Filed by: PRZYBYL ARTHUR -6.3%
4/14 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -6.0%
1/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.1%
2/27 Q4/2019 12/31/2019 EPS 1.080 ZacksConsensus 1.020 ActVsEst 0.060 - Beat -18.7%
8/7 Q2/2019 6/30/2019 EPS 1.440 ZacksConsensus 1.180 ActVsEst 0.260 - Beat -15.1%
4/14 ANI Announces Upcoming Departure of CEO -9.0%
3/2 ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules -7.8%
3/4 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
3/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.4%
3/31 Form 4 ANI PHARMACEUTICALS INC For: Mar 28 Filed by: PRZYBYL ARTHUR -6.3%
4/14 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -6.0%
1/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: